Celldex Therapeutics Company Profile (NASDAQ:CLDX)

About Celldex Therapeutics

Celldex Therapeutics logoCelldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CLDX
  • CUSIP: 15117B10
Key Metrics:
  • Previous Close: $3.26
  • 50 Day Moving Average: $3.45
  • 200 Day Moving Average: $3.72
  • 52-Week Range: $101,248,000.00 - $2.85
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.83
  • P/E Growth: 0.00
  • Market Cap: $330.07M
  • Outstanding Shares: 101,248,000
  • Beta: 2.67
Profitability:
  • Net Margins: -1,923.41%
  • Return on Equity: -51.46%
  • Return on Assets: -44.35%
Debt:
  • Current Ratio: 11.26%
  • Quick Ratio: 11.26%
Additional Links:
Companies Related to Celldex Therapeutics:

Analyst Ratings

Consensus Ratings for Celldex Therapeutics (NASDAQ:CLDX) (?)
Ratings Breakdown: 5 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.55)
Consensus Price Target: $7.75 (137.73% upside)

Analysts' Ratings History for Celldex Therapeutics (NASDAQ:CLDX)
Show:
DateFirmActionRatingPrice TargetDetails
11/10/2016Roth CapitalReiterated RatingBuy$7.00View Rating Details
11/8/2016WedbushReiterated RatingNeutral$3.00View Rating Details
11/8/2016Cantor FitzgeraldReiterated RatingBuy$9.00View Rating Details
11/7/2016AegisInitiated CoverageBuyView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$16.00View Rating Details
8/11/2016Jefferies Group LLCReiterated RatingHold$4.00 -> $5.00View Rating Details
6/7/2016Cowen and CompanyReiterated RatingOutperform$12.00View Rating Details
3/8/2016HC WainwrightLower Price TargetBuy$25.00 -> $6.00View Rating Details
3/7/2016Leerink SwannDowngradeOutperform -> Market Perform$30.00 -> $4.00View Rating Details
3/7/2016Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformView Rating Details
3/7/2016GuggenheimDowngradeBuy -> NeutralView Rating Details
6/1/2015WBB SecuritiesReiterated RatingBuy$30.00 -> $40.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Celldex Therapeutics (NASDAQ:CLDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2017        
11/7/2016Q3 2016($0.33)($0.29)$1.09 million$2.20 millionViewN/AView Earnings Details
8/8/2016Q2($0.34)($0.32)$0.96 million$1.39 millionViewListenView Earnings Details
5/5/2016Q1 16($0.35)($0.35)$1.06 million$1.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.35)($0.33)$0.80 million$1.80 millionViewListenView Earnings Details
11/5/2015Q3($0.35)($0.32)ViewN/AView Earnings Details
8/10/2015Q215($0.34)($0.33)$2.20 millionViewListenView Earnings Details
4/29/2015Q115($0.36)($0.33)$0.52 million$0.49 millionViewN/AView Earnings Details
2/24/2015Q314($0.35)($0.36)$0.49 million$1.50 millionViewN/AView Earnings Details
11/5/2014Q3($0.31)($0.31)$0.43 million$1.10 millionViewN/AView Earnings Details
8/6/2014Q214($0.32)($0.32)$0.38 million$0.60 millionViewN/AView Earnings Details
5/1/2014($0.25)($0.33)$0.34 million$0.40 millionViewN/AView Earnings Details
3/3/2014Q413($0.28)($0.27)$0.27 million$0.62 millionViewN/AView Earnings Details
11/5/2013Q313($0.24)($0.29)$0.09 million$1.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.22)($0.24)$1.57 million$0.97 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.22)($0.23)$2.65 million$2.41 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.25)($0.27)$2.45 million$3.65 millionViewN/AView Earnings Details
11/1/2012Q312($0.24)($0.25)$2.07 million$3.11 millionViewN/AView Earnings Details
8/10/2012($0.25)($0.23)ViewN/AView Earnings Details
5/3/2012($0.25)($0.27)ViewN/AView Earnings Details
3/7/2012($0.26)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celldex Therapeutics (NASDAQ:CLDX)
Current Year EPS Consensus Estimate: $-1.31 EPS
Next Year EPS Consensus Estimate: $-1.15 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($0.39)($0.34)($0.36)
Q2 20167($0.39)($0.29)($0.34)
Q3 20166($0.38)($0.27)($0.32)
Q4 20164($0.34)($0.26)($0.31)
Q1 20171($0.27)($0.27)($0.27)
Q2 20171($0.27)($0.27)($0.27)
Q3 20171($0.20)($0.20)($0.20)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celldex Therapeutics (NASDAQ:CLDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celldex Therapeutics (NASDAQ:CLDX)
Insider Ownership Percentage: 4.20%
Institutional Ownership Percentage: 55.99%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/2/2016Tibor KelerVPBuy3,000$3.32$9,960.00View SEC Filing  
11/23/2015Avery W. CatlinCFOSell25,000$18.00$450,000.00View SEC Filing  
8/25/2015Larry EllbergerDirectorBuy5,000$14.00$70,000.00View SEC Filing  
8/20/2015Larry EllbergerDirectorBuy5,000$15.00$75,000.00View SEC Filing  
8/18/2015Larry EllbergerDirectorBuy5,000$15.95$79,750.00View SEC Filing  
8/13/2015Anthony S MarucciCEOBuy5,800$16.81$97,498.00View SEC Filing  
8/13/2015Larry EllbergerDirectorBuy5,000$16.59$82,950.00View SEC Filing  
6/15/2015Avery W CatlinCFOSell25,000$24.59$614,750.00View SEC Filing  
12/6/2013Avery CatlinCFOSell183,333$24.50$4,491,658.50View SEC Filing  
12/6/2013Larry EllbergerDirectorSell17,728$24.50$434,336.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Celldex Therapeutics (NASDAQ:CLDX)
DateHeadline
fool.com logoLooking Back at David Gardner's Worst Stock Picks of the Past 3 Years (NASDAQ:CLDX)
www.fool.com - February 23 at 9:20 PM
News Icon59 hedge funds sold their entire positions in Celldex Therapeutics, Inc. (CLDX) - Post Analyst (NASDAQ:CLDX)
postanalyst.com - February 22 at 4:29 PM
News IconCelldex Therapeutics, Inc. (NASDAQ:CLDX) Earnings At A Glance: Consensus Projections in Spotlight - Winfield Review (NASDAQ:CLDX)
winfieldreview.com - February 22 at 11:52 AM
News IconShares in View: Celldex Therapeutics Inc. (CLDX) - Benton Bulletin (NASDAQ:CLDX)
bentonbulletin.com - February 17 at 5:52 PM
News IconWhat's Happening To These Stocks? – Omnicell, Inc. (OMCL), Celldex Therapeutics, Inc. (CLDX) - Post Analyst (NASDAQ:CLDX)
postanalyst.com - February 17 at 5:52 PM
nasdaq.com logoCelldex Therapeutics To Present At Leerink Global Conference; Webcast At 9:30AM (NASDAQ:CLDX)
www.nasdaq.com - February 16 at 10:48 AM
News IconSADIF Analytics releases new summary due diligence report for Celldex Therapeutics Inc ($CLDX). (NASDAQ:CLDX)
reports.pr-inside.com - February 16 at 10:48 AM
News IconPeeling Back The Layers on Celldex Therapeutics, Inc. (NASDAQ:CLDX): Analysts & Street Weigh In - Winfield Review (NASDAQ:CLDX)
winfieldreview.com - February 15 at 3:10 AM
News IconHot Stock Update: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - HugoPress (NASDAQ:CLDX)
hugopress.com - February 14 at 5:06 PM
News IconQuick Review on Trend Indicator Levels: Celldex Therapeutics Inc. (CLDX) - BVN (NASDAQ:CLDX)
bvnewsjournal.com - February 14 at 5:06 PM
finance.yahoo.com logoCelldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call (NASDAQ:CLDX)
finance.yahoo.com - February 13 at 4:59 PM
News IconColumbia Wanger Asset Management is Buying Celldex Therapeutics Inc. (NASDAQ:CLDX) Shares - Small Cap Exclusive (press release) (NASDAQ:CLDX)
smallcapexclusive.com - February 11 at 4:25 PM
News IconInvestor Update: Looking at Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Benton Bulletin (NASDAQ:CLDX)
bentonbulletin.com - February 11 at 2:41 AM
News IconForward Earnings Estimate of Celldex Therapeutics, Inc.(CLDX) - Highland Mirror (NASDAQ:CLDX)
www.highlandmirror.com - February 11 at 2:41 AM
fool.com logoWhy Celldex Therapeutics Stock Fell by Almost 10% in January ... - Motley Fool (NASDAQ:CLDX)
www.fool.com - February 8 at 9:40 PM
News IconStock to Watch: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - The Oracle Examiner (NASDAQ:CLDX)
oracleexaminer.com - February 8 at 9:40 PM
istreetwire.com logoStocks Trending Alert: Celldex Therapeutics, Inc. (CLDX), Kansas City Southern (KSU), Tiffany & Co. (TIF) - iStreetWire (NASDAQ:CLDX)
istreetwire.com - February 8 at 9:40 PM
biz.yahoo.com logoCELLDEX THERAPEUTICS, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statem (NASDAQ:CLDX)
biz.yahoo.com - February 8 at 4:38 PM
fool.com logoWhy Celldex Therapeutics Stock Fell by Almost 10% in January (NASDAQ:CLDX)
www.fool.com - February 8 at 10:05 AM
News IconMartin Schulz is drawing nearer to Angela Merkel in German election polls (NASDAQ:CLDX)
mundoaguaysaneamiento.net - February 3 at 4:36 PM
fool.com logoForget Celldex Therapeutics, Inc.: These 2 Stocks Are Better Buys - Motley Fool (NASDAQ:CLDX)
www.fool.com - February 1 at 4:36 PM
fool.com logoForget Celldex Therapeutics, Inc.: These 2 Stocks Are Better Buys (NASDAQ:CLDX)
www.fool.com - February 1 at 8:46 AM
News IconEarnings Snapshot & Analysts Target Update on Celldex Therapeutics, Inc. (NASDAQ:CLDX)? - Wall Street Beacon (NASDAQ:CLDX)
wsbeacon.com - January 31 at 9:47 PM
News IconLevels in Review for Celldex Therapeutics, Inc. (NASDAQ:CLDX) - The Tribune (NASDAQ:CLDX)
lakecitytribune.com - January 30 at 5:13 PM
News IconPeeling Back The Layers on Celldex Therapeutics, Inc. (NASDAQ:CLDX): Analysts & Street Weigh In - Wall Street Beacon (NASDAQ:CLDX)
wsbeacon.com - January 30 at 5:13 PM
News IconInvestor Watch: Volatility Review for Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Gilbert Daily (NASDAQ:CLDX)
gilbertdaily.com - January 30 at 6:52 AM
News IconIs There Inherent Value in Celldex Therapeutics, Inc. (NASDAQ:CLDX)? Analysts Delve Into The Stock - Wall Street Beacon (NASDAQ:CLDX)
wsbeacon.com - January 30 at 6:52 AM
News IconAnalyst Buzz: Celldex Therapeutics, Inc. (NASDAQ:CLDX), SunCoke Energy, Inc. (NYSE:SXC) - The Newburgh Press (NASDAQ:CLDX)
newburghpress.com - January 29 at 2:37 AM
News IconTale of the Tape: Technical Recap for Celldex Therapeutics Inc. (CLDX) - Rives Journal (NASDAQ:CLDX)
rivesjournal.com - January 29 at 2:37 AM
News IconAnalyst Research Report on Celldex Therapeutics, Inc. (CLDX ... - Highland Mirror (NASDAQ:CLDX)
www.highlandmirror.com - January 26 at 10:27 PM
News IconWhat Are the Technicals Saying About These Shares: Celldex Therapeutics Inc. (CLDX) - Sherwood Daily (NASDAQ:CLDX)
sherwooddaily.com - January 26 at 5:24 PM
News IconCelldex Therapeutics, Inc. (NASDAQ:CLDX) Upgrades/Downgrades review - The Newburgh Press (NASDAQ:CLDX)
newburghpress.com - January 26 at 5:24 PM
News IconEarnings in Full Force, Analysts Take Aim at Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Wall Street Beacon (NASDAQ:CLDX)
wsbeacon.com - January 24 at 9:56 PM
News IconCelldex Therapeutics, Inc. (NASDAQ:CLDX) Quarterly EPS Projection At $-0.31 - Stock Observer (NASDAQ:CLDX)
www.thestockobserver.com - January 24 at 9:56 PM
News IconLong term Growth Analysis of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - The Newburgh Press (NASDAQ:CLDX)
newburghpress.com - January 24 at 9:56 PM
News IconPeeling Back The Layers on Celldex Therapeutics, Inc. (NASDAQ:CLDX): Sell-Side Weighs In - Wall Street Beacon (NASDAQ:CLDX)
wsbeacon.com - January 24 at 9:56 PM
News IconAnalysts Pounding The Pavement on Celldex Therapeutics, Inc. (NASDAQ:CLDX): Consensus Update - Wall Street Beacon (NASDAQ:CLDX)
wsbeacon.com - January 24 at 2:39 AM
News IconIndicator Review on Shares of Celldex Therapeutics Inc. (CLDX) - Sherwood Daily (NASDAQ:CLDX)
sherwooddaily.com - January 23 at 2:21 AM
fool.com logo3 Beaten-Down Biotech Stocks You Can Buy Right Now (NASDAQ:CLDX)
www.fool.com - January 20 at 5:29 PM
News IconKeeping Tabs on Technicals for Celldex Therapeutics Inc. (CLDX) - Sherwood Daily (NASDAQ:CLDX)
sherwooddaily.com - January 20 at 3:36 AM
News IconDevling Into Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), What Are Analysts Predicting for 2017? - Wall Street Beacon (NASDAQ:CLDX)
wsbeacon.com - January 20 at 3:36 AM
News IconShares of Clovis Oncology, Inc. (NASDAQ:CLVS) Sees Large Outflow of Money (NASDAQ:CLDX)
vouxmagazine.com - January 18 at 4:38 PM
News IconWill The Needle Move For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:CLDX)
wsbeacon.com - January 18 at 3:13 AM
News IconEarnings Fever Sweeping In, What Are Analysts Expecting From Celldex Therapeutics, Inc. (NASDAQ:CLDX)? - Wall Street Beacon (NASDAQ:CLDX)
wsbeacon.com - January 18 at 3:13 AM
News IconEPS Of Celldex Therapeutics, Inc. (NASDAQ:CLDX) At $-0.31 - Stock Observer (NASDAQ:CLDX)
www.thestockobserver.com - January 18 at 3:13 AM
istreetwire.com logoStocks To Watch: Nuance Communications, Inc. (NUAN), DISH ... - iStreetWire (NASDAQ:CLDX)
istreetwire.com - January 16 at 4:23 PM
News IconNews Impact Score Of Celldex Therapeutics, Inc. (NASDAQ:CLDX) Set At 77 - Stock Observer (NASDAQ:CLDX)
www.thestockobserver.com - January 16 at 4:23 PM
News IconWall Street and Armchair Analysts Weigh in on Celldex Therapeutics, Inc. (NASDAQ:CLDX) Heading Into The New Year - Wall Street Beacon (NASDAQ:CLDX)
wsbeacon.com - January 12 at 9:40 PM
News IconCelldex Therapeutics Inc CLDX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CLDX)
www.bioportfolio.com - January 12 at 4:40 PM
News IconStock Getting Tripped Up In Session: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Wall Street Beacon (NASDAQ:CLDX)
wsbeacon.com - January 11 at 9:44 PM

Social

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Where is Celldex Therapeutics' stock going? Where will Celldex Therapeutics' stock price be in 2017?

11 equities research analysts have issued 12 month target prices for Celldex Therapeutics' stock. Their forecasts range from $3.00 to $16.00. On average, they expect Celldex Therapeutics' share price to reach $7.75 in the next twelve months.

When will Celldex Therapeutics announce their earnings?

Celldex Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 14th 2017.

Who owns Celldex Therapeutics stock?

Celldex Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (19.09%), KLP Enterprises LLC (6.78%), Franklin Resources Inc. (6.16%), Columbia Wanger Asset Management LLC (6.12%), State Street Corp (4.27%) and Frontier Capital Management Co. LLC (1.55%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Avery W Catlin, Larry Ellberger and Tibor Keler.

Who sold Celldex Therapeutics stock? Who is selling Celldex Therapeutics stock?

Celldex Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Numeric Investors LLC, State Street Corp, Franklin Resources Inc., Renaissance Technologies LLC, Frontier Capital Management Co. LLC, Metropolitan Life Insurance Co. NY and National Planning Corp.

Who bought Celldex Therapeutics stock? Who is buying Celldex Therapeutics stock?

Celldex Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including KLP Enterprises LLC, FMR LLC, Columbia Wanger Asset Management LLC, Deerfield Management Co., A.R.T. Advisors LLC, Russell Investments Group Ltd., Federated Investors Inc. PA and Paulson & CO. Inc.. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Larry Ellberger and Tibor Keler.

How do I buy Celldex Therapeutics stock?

Shares of Celldex Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Celldex Therapeutics stock cost?

One share of Celldex Therapeutics stock can currently be purchased for approximately $3.26.

Celldex Therapeutics (NASDAQ:CLDX) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Earnings History Chart

Earnings by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Dividend History Chart

Dividend Payments by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Last Updated on 2/27/2017 by MarketBeat.com Staff